Overview

Metformin for Treatment of Antipsychotic-induced Dyslipidemia

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:
0

Participant gender:
All

Summary

Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Metformin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic-induced dyslipidemia.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Central South University

Treatments:

Antipsychotic Agents
Metformin

Criteria

Inclusion Criteria:

Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria for
schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less
than 12 months taking only one antipsychotic stable outpatient the total score of Positive
and Negative Syndrome Scale (PANSS)≤60.

-

Exclusion Criteria:

liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or
diabetes mellitus